로딩 중…
지수 로딩 중…
Medy-Tox Inc.
086900· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩83,900-4.00%
2026-06-19
Price Chart
Medy-Tox Inc.-48.53%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 612.34B KRW |
| Revenue | 244.02B KRW |
| Net Income | -3.02B KRW |
| Total Assets | 564.78B KRW |
| Net Assets | 379.71B KRW |
| Employees | 776 |
| Value | |
| P/B | 1.61x |
| P/S | 2.51x |
| FCF Yield | 7.47% |
| Profitability | |
| ROE | -0.79% |
| ROA | -0.53% |
| Op. Margin | -0.73% |
| Revenue Growth | -5.11% |
| Earnings Growth | 107.05% |
| Financial Health | |
| Debt Ratio | 148.74% |
| Total Debt | 125.12B KRW |
| FCF | 45.75B KRW |
| Cash | 42.48B KRW |
| Current Ratio | 1.01x |
| Dividend | |
| Div. Yield | 1.37% |
| Div. Growth | 9.09% |
| Performance | |
| 1Y Return | -48.53% |
| 1M Return | -13.86% |
| From 52W High | -53.34% |
| 1Y MDD | -56.32% |
| Trading | |
| Volume | 49,836 shares |
| Foreign Own. | 15.57% |
| Per Share | |
| EPS | 2,660 KRW |
| BPS | 53,877 KRW |
Company Info
Established in 2000 and listed on KOSDAQ in 2009, Meditox engages in the research, development, manufacturing, and sale of Botulinum Toxin Type A and biopharmaceuticals. The company's main products are Meditoxin Inj., Coretox, and Innotox, developed with proprietary original technology. With the KFDA product approval for Neurtoxin in 2023, it is expanding into domestic and international markets while diversifying its portfolio with hyaluronic acid fillers, liquid toxin formulations for US entry, and genetically recombinant toxins. Meditox is headquartered in Cheongwon-gun, Chungcheongbuk-do.